A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma
Eastern Mediterranean Health Journal · 27.06.2023 · 29 (6) · 462-473
DOI: 10.26719/emhj.23.087 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Eastern Mediterranean Health Journal, online erschienen am 27.06.2023. Verfasst von Ahmet Dirican und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Medicalpark Hospital, Izmir University of Economics, Izmir, Türkiye. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is a significant health problem, and the associated mortality rate is increasing.
Aim
We aimed to determine the clinical characteristics and prognosis for HCC in member countries of the OncoBridge Study Group.
Methods
We recruited 630 patients diagnosed with HCC between 2013 and 2019 from 4 countries (Türkiye, Russia, Georgia, and Greece). Univariate and multivariate analyses were conducted to investigate clinical and laboratory prognostic factors. Receiver operating characteristic (ROC) analysis was used to determine the prognostic value of the neutrophil to lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) value.
Results
The 3 most common etiological factors were hepatitis B infection (39.7%), hepatitis C virus infection (17.0%) and non-alcoholic fatty liver disease (9.0%). Median overall survival for the whole group was 25 [95% confidence interval (CI): 15.7–34.2] months. Cut-off values for AFP and NLR were accepted as 200 ng/mL and 3.45, respectively. The area under the ROC curve values for AFP, NLR and NLR+AFP were 0.625 (95% CI: 0.547–0.704), 0.589 (95% CI: 0.512–0.667) and 0.657 (95% CI: 0.583–0.731). From the multivariate analysis, advanced tumour size, lymph node involvement and metastasis (TNM) stage, presence of cirrhosis, high AFP, and high NLR values were associated with poor survival.
Conclusion
AFP, NLR, advanced TNM, and presence of cirrhosis may predict prognosis in patients with HCC. Studies involving more countries are needed to corroborate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Medicalpark Hospital, Izmir University of Economics, Izmir, Türkiye.
- Department of Medical Oncology, Ankara Numune Education and Research Hospital, Health Sciences University, Ankara, Türkiye.
- World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow, Russia.
- Department of Medical Oncology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Türkiye.
- Cancer Research Unit and Oncology Surgery, National Cancer Center, Tbilisi State Medical University, Tbilisi, Georgia.
- Department of Medical Oncology, Medical Faculty, Manisa Celal Bayar University, Manisa, Türkiye.
Zitieren
APA
Dirican, A., Uncu, D., Sekacheva, M., Artaç, M., Aladashvil, A., Erdogan, A., Kaplan, M., Alacacıoğlu, A., Boukovinas, I., & Turhal, N. (2023). A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma. Eastern Mediterranean Health Journal, 29(6), 462-473. https://doi.org/10.26719/emhj.23.087
Vancouver
Dirican A, Uncu D, Sekacheva M, Artaç M, Aladashvil A, Erdogan A, et al. A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma. Eastern Mediterranean Health Journal. 2023;29(6):462-473. doi:10.26719/emhj.23.087
BibTeX
@article{Dirican2023,
author = {Dirican, Ahmet and Uncu, Dogan and Sekacheva, Marina and Artaç, Mehmet and Aladashvil, Archil and Erdogan, Atike and Kaplan, Muhammet and Alacacıoğlu, Ahmet and Boukovinas, Ioannis and Turhal, Nazim},
title = {A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma},
journal = {Eastern Mediterranean Health Journal},
year = {2023},
volume = {29},
number = {6},
pages = {462--473},
doi = {10.26719/emhj.23.087}
}
EUVIMED